Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2010 by Center for Clinical Pharmacology Research Bdbeq S.A..
Recruitment status was:  Not yet recruiting
Laboratorio Elea S.A.C.I.F. y A.
Information provided by:
Center for Clinical Pharmacology Research Bdbeq S.A. Identifier:
First received: October 26, 2010
Last updated: NA
Last verified: October 2010
History: No changes posted
The proposed study was designed as a randomized two-sequence, two period crossover trial to assess the bioequivalence, pharmacokinetic profiling and safety of a brand generic formulation of darifenacin [Darisec(R) 7.5 mg] vs. the innovator [Enablex(R)7.5 mg]in healthy volunteers in postprandial state.

Condition Intervention Phase
Drug: Darifenacin
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: Comparative Bioavailability of Darifenacin Extended Release Oral Formulation [Darisec(R)7.5 mg vs. Enablex(R)7.5 mg]: Single-dose, Postprandial State, Randomized, Two-sequence, Two-period, Crossover Study in Healthy Volunteers.

Resource links provided by NLM:

Further study details as provided by Center for Clinical Pharmacology Research Bdbeq S.A.:

Primary Outcome Measures:
  • Extent of absorption [ Time Frame: 72 hours ]
    Extent of absorption will be measured using the area under the plasma concentration of darifenacin vs time from time 0 to the last sample point (AUC0-t) and from time 0 to infinity (AUC0-inf.

  • Rate of absorption [ Time Frame: 72 ]
    Rate of abosorption will be measured using peak concentration of darifenacin (Cmax)taken from the concentration vs. time curve.

Secondary Outcome Measures:
  • Time to peak concentration (tmax) [ Time Frame: 72 ]
    Tmax is the time elapsed from ingestion of darifenacin tablets to plasma peak concentration (Cmax)

  • Elimination rate constant (Ke) [ Time Frame: 72 hours ]
    The elimination rate constant is the fractional rate of drug disappearance form the peripheral compartement, measured in the log-linear elimination phase.

  • Elimination Half-life (t1/2e) [ Time Frame: 72 hours ]
    t1/2e is the time in which the concentration in the log-linear elimination phase drops by half.

  • Systemic clearance (Cls) [ Time Frame: 72 hours ]
    Cls is the amount of plasma volume units that are totally cleared of the drug in the unit of time.

Estimated Enrollment: 24
Study Start Date: December 2010
Estimated Study Completion Date: February 2011
Estimated Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Darisec(R) 7.5 mg Drug: Darifenacin
Single dose 7.5 mg tablets of darifenacin
Other Names:
  • Muscarinic antagonist
  • Cholinergic antagonist
  • Cholinergic agent
  • Darisec
Active Comparator: Enablex(R) 7.5 mg Drug: Darifenacin
Single dose 7.5 mg tablets of Darifenacin
Other Names:
  • Muscarinec antagonist
  • Cholinergic antagonist
  • Cholinergic agent
  • Enablex

Detailed Description:

Darifenacin is a muscarinic receptor antagonist drug used to treat overactive bladder. There is a new formulation of darifenacin extended release developed by an argentinian pharmaceutical company. A bioequivalence study will be performed to validate pharmaceutical development before introducing the product in the market.

The purpose in this study is to evaluate the relative bioavailability, pharmacokinetic profiling and safety of a brand generic formulation of darifenacin [Darisec(R) 7.5 mg] vs. the innovator [Enablex(R) 7.5 mg]in 24 healthy uruguayan volunteers after a high fat breakfast of 1000 calories (50% fat, 35% carbohydrates, and 15% proteins)to establish their average bioequivalence.

The bioequivalence will be evaluated using:

  • The Area Under the Curve (AUC),
  • The peak plasma concentration (Cmax).

The pharmacokinetic characteristics of the drug formulations will be described calculating:

  • The time to peak concentration (Tmax)
  • The elimination constant (Ke)
  • The elimination half-life (t1/2e)
  • The systemic clearance (Cls)

Safety will be evaluated recording:

  • Reported adverse events
  • Vital signs (blood pressure, heart rate, body temperature)
  • Laboratory analysis (hemogram, hepatic enzymes, creatinine, sugar in blood, etc.)
  • EKG and chest XRays

Bioequivalence will be claimed if the drugs comply with local and FDA regulatory requirements:

  • Mean AUCt/AUCr and 90% confidence interval within 0.80-1.25
  • Mean Cmaxt/Cmaxr and 90% confidence interval within 0.80-1.25

Pharmacokinetic profiling will be evaluated by describing the pharmacokinetic characteristics of both drug in adequate two-way tables.

Safety will be evaluated comparing incidence of adverse events/adverse effects for both products.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male or female subjects 18 to 50 years of age (inclusive).
  • In good health, as determined by lack of clinically significant abnormalities at screening as judged by the physician.
  • Female subjects are required to use a medically accepted method of hormonal contraception or abstinence throughout the entire study period and for one week after the study is completed.
  • Body mass index within the range of 18.5 and 29.9 kg/m2 and weight at least 45 kg.

Exclusion Criteria:

  • Known hypersensitivity or severe adverse event to darifenacin or similar drugs.
  • Urinary, retention, narrow-angle glaucoma, myasthenia gravis, severe hepatic impairment, severe ulcerative colitis, toxic megacolon.
  • Symptomatic hiatus hernia, erosive or symptomatic gastroesophageal reflux disease/heartburn (>2 days in a week), severe constipation, gastrointestinal obstructive disorder, and gastric retention.
  • Clinically significant cardiac abnormalities, fainting, low blood pressure upon standing, irregular heartbeats.
  • Acute or chronic bronchospastic disease(including asthma and Chronic Obstructive Pulmonary Disease).
  • Clinically significant drug allergy or history of atopic allergy (asthma, urticaria, eczematous dermatitis).
  • Smokers of more than 5 cigarettes a week.
  • Regular use of any drug known to induce or inhibit hepatic drug metabolism (particularly those that affect CYP2D6) within 30 days prior to each study drug administration.
  • Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs which may jeopardize participation in the study.
  • Immunodeficiency diseases, including a positive HIV (Elisa or Western blot) test result.
  • Positive Hepatitis B Surface antigen (HBsAg) or Hepatitis C results.
  • Drug or alcohol abuse within the 6 months prior to dosing.
  • Use of prescription drugs within 1 month prior to dosing, or over-the-counter medication (vitamins, herbal supplements, dietary supplements)within 2 weeks prior to dosing. Paracetamol and ibuprofen are acceptable.
  • Participation in any clinical investigation within 12 weeks prior to dosing.
  • Donation or loss of 400 ml or more of blood within 8 weeks prior to dosing.
  • Significant illness within 2 weeks prior to dosing.
  • Other protocol-defined inclusion/exclusion criteria may apply.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01229280

Contact: Federico Santoro, MD +541143794300
Contact: Joanna Steimberg, MBA +541143794330

Center for Clinical Pharmacology Research (CCPR) Bdbeq S.A. Hospital Italiano. Not yet recruiting
Montevideo, Uruguay, 11600
Contact: Francisco E. Estevez-Carrizo, M.D.    +59824876288   
Contact: Mónica Cedrés, Pharm. B.    +59824876288   
Principal Investigator: Susana Parrillo, M.D.         
Sponsors and Collaborators
Center for Clinical Pharmacology Research Bdbeq S.A.
Laboratorio Elea S.A.C.I.F. y A.
Study Director: Francisco E. Estevez-Carrizo, MD Univerisity of Montevideo. Biomedical Science Center.Prudencio de Pena 2440, 11600 Montevideo. Uruguay
Principal Investigator: Susana Parrillo, M.D. Center for Clinical Pharmacology Research Bdbeq S.A., Br. Artigas 1632. c.p. 11600 Montevideo. Uruguay.
  More Information

Responsible Party: Francisco E. Estevez-Carrizo, Center for Clinical Pharmacology Research Bdbeq S.A. Identifier: NCT01229280     History of Changes
Other Study ID Numbers: BDBEQ_DFNLP/ELEA_010
Study First Received: October 26, 2010
Last Updated: October 26, 2010

Keywords provided by Center for Clinical Pharmacology Research Bdbeq S.A.:
Healthy volunteers

Additional relevant MeSH terms:
Muscarinic Antagonists
Cholinergic Agents
Cholinergic Antagonists
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents processed this record on May 22, 2017